121 related articles for article (PubMed ID: 26600220)
1. Hepatitis C: An Eastern Perspective.
Dan YY; Lim SG
Gastroenterol Clin North Am; 2015 Dec; 44(4):793-805. PubMed ID: 26600220
[TBL] [Abstract][Full Text] [Related]
2. Urgency to treat patients with chronic hepatitis C in Asia.
Kao JH; Ahn SH; Chien RN; Cho M; Chuang WL; Jeong SH; Liu CH; Paik SW
J Gastroenterol Hepatol; 2017 May; 32(5):966-974. PubMed ID: 28005275
[TBL] [Abstract][Full Text] [Related]
3. Management of hepatitis C virus infection in the Asia-Pacific region: an update.
Lim SG; Aghemo A; Chen PJ; Dan YY; Gane E; Gani R; Gish RG; Guan R; Jia JD; Lim K; Piratvisuth T; Shah S; Shiffman ML; Tacke F; Tan SS; Tanwandee T; Win KM; Yurdaydin C
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):52-62. PubMed ID: 28404015
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
5. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
[TBL] [Abstract][Full Text] [Related]
6. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6.
Nguyen NH; Nguyen MH
Gastroenterol Clin North Am; 2015 Dec; 44(4):871-81. PubMed ID: 26600225
[TBL] [Abstract][Full Text] [Related]
7. A 2015 roadmap for the management of hepatitis C virus infections in Asia.
Lim SG; Dan YY
Korean J Intern Med; 2015 Jul; 30(4):423-33. PubMed ID: 26161008
[TBL] [Abstract][Full Text] [Related]
8. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
Asselah T; Bourlière M
Gastroenterol Clin North Am; 2015 Dec; 44(4):859-70. PubMed ID: 26600224
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C.
Bickerstaff C
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):787-800. PubMed ID: 26289734
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.
Cammà C; Petta S; Cabibbo G; Ruggeri M; Enea M; Bruno R; Capursi V; Gasbarrini A; Alberti A; Craxì A;
J Hepatol; 2013 Oct; 59(4):658-66. PubMed ID: 23707373
[TBL] [Abstract][Full Text] [Related]
14. [Chronic hepatitis C infection--eradication of the virus].
Ben Ari Z
Harefuah; 2014 Jul; 153(7):392-3, 433. PubMed ID: 25189028
[TBL] [Abstract][Full Text] [Related]
15. Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?
Lagging M; Alsiö S; Hellstrand K; Norkrans G;
J Hepatol; 2011 Apr; 54(4):835-6; author reply 836-7. PubMed ID: 21145838
[No Abstract] [Full Text] [Related]
16. Therapy for hepatitis C genotype 3: moving forward.
Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of hepatitis C direct acting agents.
Shetty A; Lee M; Valenzuela J; Saab S
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):589-597. PubMed ID: 38665122
[TBL] [Abstract][Full Text] [Related]
18. What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.
Ahmed F
J Viral Hepat; 2013 May; 20(5):367-8. PubMed ID: 23565620
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
Logge C; Vettorazzi E; Fischer L; Nashan B; Sterneck M
Transpl Int; 2013 May; 26(5):527-34. PubMed ID: 23517333
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
Haj-Ali Saflo O; Hernández Guijo JM
Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
